Post Marketing Study to Evaluate the Efficacy and Safety of Solifenacin in Patients With OAB (Overactive Bladder) After TURP (Trans-urethral Resection of Prostate) or PVP (Photoselective Vaporization of Prostate)

NCT01747577 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

68

Enrollment

INDUSTRY

Sponsor class

Conditions

Overactive Bladder
Benign Prostate Hyperplasia
Transurethral Resection of Prostate
Photoselective Vaporization Prostatectomy

Interventions

DRUG: Solifenacin Succinate
DRUG: Placebo

Sponsor

Astellas Pharma Korea, Inc.